Fabtech Technologies Ltd
Incorporated in 2018, Fabtech Technologies Ltd is a biopharma engineering company.[1]
- Market Cap ₹ 682 Cr.
- Current Price ₹ 154
- High / Low ₹ 263 / 126
- Stock P/E 36.1
- Book Value ₹ 38.2
- Dividend Yield 0.00 %
- ROCE 19.8 %
- ROE 16.7 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.30.5 Cr.
- Company has high debtors of 190 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 133 | 121 | 257 | 194 | 225 | 236 | |
| 119 | 110 | 225 | 169 | 190 | 210 | |
| Operating Profit | 14 | 11 | 32 | 25 | 35 | 27 |
| OPM % | 11% | 9% | 13% | 13% | 16% | 11% |
| 5 | 2 | 2 | 6 | 4 | 30 | |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 |
| Depreciation | 0 | 0 | 1 | 2 | 2 | 2 |
| Profit before tax | 16 | 11 | 31 | 24 | 35 | 52 |
| Tax % | 27% | 29% | 27% | 27% | 25% | 26% |
| 12 | 8 | 23 | 18 | 26 | 38 | |
| EPS in Rs | 11,720.00 | 7,630.00 | 81.23 | 63.46 | 89.04 | 11.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | -3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 1% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 21% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 3 | 3 | 3 | 32 | 32 |
| Reserves | 37 | 44 | 64 | 79 | 121 | 125 | 137 |
| 1 | 9 | 19 | 34 | 8 | 62 | 42 | |
| 84 | 70 | 83 | 91 | 117 | 120 | 163 | |
| Total Liabilities | 122 | 124 | 169 | 207 | 248 | 340 | 375 |
| 2 | 2 | 3 | 4 | 5 | 55 | 55 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 11 | 5 | 14 | 14 | 36 | 28 | 24 |
| 109 | 116 | 152 | 190 | 207 | 258 | 295 | |
| Total Assets | 122 | 124 | 169 | 207 | 248 | 340 | 375 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 27 | -9 | -5 | -16 | 62 | -53 | |
| -20 | 4 | -9 | 2 | -28 | 12 | |
| 5 | 6 | 10 | 12 | -14 | 16 | |
| Net Cash Flow | 13 | 1 | -4 | -2 | 20 | -24 |
| Free Cash Flow | 21 | -3 | -6 | -16 | 61 | -76 |
| CFO/OP | 222% | -61% | -3% | -24% | 197% | -161% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 123 | 187 | 153 | 190 |
| Inventory Days | 22 | 39 | 17 | 69 | 49 | 45 |
| Days Payable | 82 | 150 | 136 | 215 | 173 | 208 |
| Cash Conversion Cycle | 51 | 25 | 5 | 41 | 29 | 27 |
| Working Capital Days | -19 | 15 | 37 | 65 | 47 | 61 |
| ROCE % | 27% | 49% | 29% | 30% | 20% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Book to Bill Ratio Ratio |
|
||
| In-house Manufacturing Share of Project Supplies % |
|||
| New Order Intake INR Lakhs |
|||
| Number of Projects Delivered Globally Count |
|||
| Proposal to Order Conversion Ratio % |
|||
| Total Unexecuted Order Book INR Lakhs |
|||
| Number of Countries of Presence Count |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Earnings conference call scheduled on 28 April 2026, 10:00 a.m., for audited FY26 results.
-
Board Meeting Intimation for Audited Financial Results And Dividend For Period Ended March 31, 2026.
1d - Board meeting on April 27, 2026 to approve FY26 audited results and consider dividend.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - DP) Regulations, 2018 for the quarter ended March 31, 2026
-
Announcement On Order Booking And Business Updates
4 Apr - Fabtech reports ₹900 crore+ order book and strategic projects in animal health, Saudi Arabia and Africa.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
27 Mar - Rupal Haria appointed Independent Director effective April 03, 2026; Aparna Sharma tenure ends April 02, 2026; committees reconstituted.
Concalls
-
Feb 2026Transcript PPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
Business Profile[1]
Fabtech provides end-to-end turnkey pharma plant solutions covering design, engineering, procurement, installation, and regulatory validation, while also offering standalone execution services like equipment supply and installation for clients with their own designs.